Unlocking New Treatments for Inflammatory and Neurodegenerative Conditions
Avinia is transforming anacardic acid from the cashew plant into a high-purity therapeutic agent designed to cross the blood-brain barrier and to promote brain health.
WHAT WE DO
OUR VISION
Avinia is dedicated to developing small molecule compounds from natural sources as novel agents for improving health and well-being.
We have chosen the products of the cashew plant as the first of our natural products for development. Anacardic acid is the main ingredient of the cashew fruit and shell. It has been used widely used in many cultures for medicinal purposes and as a dietary supplement
Unlocking new treatments for inflammatory and neurodegenerative conditions
Phase 1
Anacardic acid as a dietary ingredient.
Phase 2
Anacardic Acid as a therapeutic agent for inflammatory disorders.
Phase 3
Synthetic analogs of anacardic acid as novel drug targets.

The Cashew
The cashew fruit and seed come from Anacardium Occidentale, an angiosperm from the Anacardiacae family. Many parts of the Anacardium Occidentale, including the fruit and the nut, have been used for medicinal purposes for hundreds of years.
The main ingredients shown to have medicinal value and health benefits are the different forms of anacardic acid, which is obtained from the fruit nuts and the covering shell of the nut.
The use of anacardic acid and its analogs has remained a medicinal curiosity, without entry as a nutritional supplement or as new compounds for future drug development.

BAckground
Natural medicinal value and health benefits


Phase 1
Anacardic acid as a dietary ingredient
Purity & Scale: Synthesized >99.9% pure saturated form of anacardic acid.
Shelf-Life: Completed extended stability testing of the compound.
Safety Profile: Finished in vitro genotoxic and long-term in vivo toxicological studies.
FDA Approved: Avinia has received approval for the use of anacardic acid as a dietary supplement and have received approval from the FDA as, “generally regarded as safe” (GRAS).
Phase 2
Anacardic acid in preclinical models of inflammation and repair


Phase 3
Synthetic analogues of anacardic acid as novel drug targets
Target Mechanism: Identified the SUMOylation pathway as a key site of action for anacardic acid.
Novel Synthesis: Generated a panel of novel synthetic compounds modeled after the structure of anacardic acid
Proven Efficacy: Confirmed in vitro and in vivo effects of anarcardic acid in animal models of autoimmune inflammation.
Neurological Access: Developed compounds that are orally bioavailable and capable of crossing the blood-brain barrier.
our team
Scientific advisors & Research team

S. Sriram MS
Founder
Professor of Experimental Therapeutics

Dr. Murali Ramanathan
Scientific Advisor
Professor of Pharmaceutical Sciences & Neurology

Matt Vergne
Scientific Advisor
Professor of Pharmaceutical Sciences

John Kramer, pA
Scientific Advisor
Co-Director of IV Infusion Center

Chase Spurlock
Scientific Advisor
CEO of Decode Health & Biotechnology Innovator
Interested in our Research?
Contact us to discuss partnership opportunities, clinical data, or our development pipeline.
